Search

Your search keyword '"Nannini, Margherita"' showing total 513 results

Search Constraints

Start Over You searched for: Author "Nannini, Margherita" Remove constraint Author: "Nannini, Margherita"
513 results on '"Nannini, Margherita"'

Search Results

1. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin

2. Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour

3. Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis

4. Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report

5. Genomic Landscape Comparison of Cardiac versus Extra-Cardiac Angiosarcomas

6. Preclinical Models of Visceral Sarcomas

9. Primary malignant pericardial tumour in Lynch syndrome

10. KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study

11. 68Ga-PSMA-PET vs 18F-FDG-PET in metastatic radio-refractory differentiated thyroid cancers

12. List of Contributors

14. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib

15. KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study.

16. Data from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

17. Revised supplementary Figure 1 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

18. Revised supplementary Figure 2 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

19. Revised supplementary Table 1 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

20. Revised supplementary Table 4 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

21. Revised supplementary Table 2 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

22. Revised supplementary Table 3 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST

23. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

25. Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre

26. Metabolic pseudo-progression in a patient with metastatic KIT exon 11 GIST after one month of first-line imatinib: a case report

27. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure

28. Genomic Characterization of Rare Primary Cardiac Sarcoma Entities

29. Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

34. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy

36. Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options

37. Proposal of a molecular testing algorithm for differentiated thyroid cancer (DTC).

38. Impact of stimulated thyroglobulin and BRAF status in Stage I and ATA intermediate risk DTC

39. Are BRAF-TERT mutated differentiated thyroid cancers similar to other double mutated?

40. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

41. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations:Results from a Multi-institutional European Retrospective Study

43. 18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors.

46. SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor

47. Uterine Preservation Treatments in Sarcomas: Oncological Problems and Reproductive Results: A Systematic Review

48. Radiomics and Artificial Intelligence in Uterine Sarcomas: A Systematic Review

Catalog

Books, media, physical & digital resources